These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Induction of regulatory T cells by infliximab in Behcet's disease.
    Author: Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M.
    Journal: Invest Ophthalmol Vis Sci; 2011 Jan 21; 52(1):476-84. PubMed ID: 20861484.
    Abstract:
    PURPOSE: To determine whether infliximab induces the development of Foxp3+ T regulatory (Treg) cells in patients with Behçet's disease. METHODS: The subjects were patients with refractory uveitis caused by Behçet's disease, Vogt-Koyanagi-Harada disease, or ocular toxoplasmosis and healthy volunteers. Purified CD4+ T cells were obtained from patients with uveitis who were treated with colchicine, cyclosporine, or infliximab. Flow cytometry was used to analyze the expression of Foxp3 on CD4+ T cells. RESULTS: Foxp3 was expressed in a small percentage of CD4+ T cells (<5%) from healthy subjects and from patients with active uveitis caused by Behçet's disease, Vogt-Koyanagi-Harada disease, or ocular toxoplasmosis. The percentage of Foxp3+ cells among CD4+ T cells was significantly decreased in patients with active uveitis compared with patients with inactive uveitis in the remission stage. Foxp3 was expressed at a similar level in CD4+ T cells from healthy donors, colchicine-treated patients, and cyclosporine-treated patients, whereas infliximab-treated patients expressed much higher percentages of Foxp3+ cells. Patients who had a high population of Foxp3+ cells during infliximab treatment did not experience any subsequent episodes of acute uveitis. On the other hand, patients with a low population of Foxp3+ cells did experience ocular inflammatory episodes. T cells exposed to infliximab in vitro greatly expressed Foxp3 and produced TGFβ, and the Treg cells significantly suppressed the activation of bystander T cells in vitro. CONCLUSIONS: Anti-TNF-α therapy may be useful for patients with ocular complications of Behçet's disease who have a decreased percentage of peripheral Treg cells.
    [Abstract] [Full Text] [Related] [New Search]